Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026

Fineline Cube May 19, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Deals

Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing

Fineline Cube Jan 26, 2025

Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...

Company Deals

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development

Fineline Cube Jan 26, 2025

Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...

Company Deals

Sinopharm Partners with Biogen for Comprehensive Service Agreement

Fineline Cube Jan 26, 2025

China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...

Company Drug

Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China

Fineline Cube Jan 26, 2025

German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...

Company Deals

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits

Fineline Cube Jan 26, 2025

Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...

Company Drug

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts

Fineline Cube Jan 26, 2025

Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...

Company Medical Device

Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA

Fineline Cube Jan 26, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...

Company Digital Drug

China Medical System Partners with MabGeek for Innovative Drug MG-K10

Fineline Cube Jan 26, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...

Company Drug

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062

Fineline Cube Jan 25, 2025

BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...

Company Deals

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

Fineline Cube Jan 24, 2025

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...

Company Drug

Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...

Company Deals

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology

Fineline Cube Jan 24, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Medical Device

Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter

Fineline Cube Jan 24, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval from Peru’s...

Company Drug

Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus

Fineline Cube Jan 24, 2025

China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...

Company Medical Device

Accuray’s Tomo C System Completes Treatment of First 100 Patients in China

Fineline Cube Jan 24, 2025

US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the...

Company Deals

Ascentage Pharma Prices US IPO at USD 17.25 per ADS

Fineline Cube Jan 24, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...

Company Drug

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...

Company Drug

Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer

Fineline Cube Jan 24, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a...

Company Drug

Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA

Fineline Cube Jan 24, 2025

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the...

Company Deals

Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease

Fineline Cube Jan 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement...

Posts pagination

1 … 222 223 224 … 667

Recent updates

  • Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production
  • Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026
  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Company Drug

Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.